What are the contraindications to starting Nurtec (rimegepant)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 30, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Contraindications to Starting Nurtec (Rimegepant)

Nurtec (rimegepant) has only one absolute contraindication: a history of hypersensitivity reaction to rimegepant, Nurtec ODT, or any of its components. 1

Absolute Contraindication

  • Hypersensitivity reactions including dyspnea, rash, or any allergic response to rimegepant or its components constitute the sole FDA-labeled contraindication 1
  • Delayed serious hypersensitivity reactions can occur days after administration, making any prior reaction a permanent contraindication 1
  • If hypersensitivity occurs, discontinue Nurtec immediately and do not rechallenge 1

Critical Precautions and Avoidance Situations

Severe Hepatic Impairment

  • Rimegepant is not recommended in patients with severe hepatic impairment (Child-Pugh Class C) 2
  • Systemic exposure increases 2.0-fold for total concentrations and 3.9-fold for unbound concentrations in severe hepatic impairment 2
  • Mild to moderate hepatic impairment shows <65% increase in exposure and does not require dose adjustment 2

Drug Interactions Requiring Avoidance

Strong CYP3A4 inhibitors:

  • Avoid concomitant administration with strong CYP3A4 inhibitors entirely 1
  • Examples include ketoconazole, itraconazole, clarithromycin 1

Moderate CYP3A4 inhibitors:

  • Avoid another dose of Nurtec within 48 hours when coadministered with moderate CYP3A4 inhibitors 1

Strong or moderate CYP3A inducers:

  • Avoid concomitant use as these may lead to loss of efficacy 1
  • Examples include rifampin, phenytoin, carbamazepine 1

Potent P-glycoprotein inhibitors:

  • Avoid another dose within 48 hours when coadministered with potent P-gp inhibitors 1
  • Cyclosporine and quinidine increase rimegepant exposure by 50-67% 3

Important Clinical Context

  • Unlike triptans, rimegepant has no vasoconstrictive properties, making cardiovascular disease NOT a contraindication 4
  • No signal of hepatotoxicity has been identified in long-term safety studies up to 52 weeks 5
  • No evidence of medication-overuse headache or drug abuse potential 5
  • Rimegepant is safe and well-tolerated with most adverse events being mild upper respiratory infections or nasopharyngitis 5

Pregnancy and Lactation Considerations

  • While not absolute contraindications, discuss adverse effects during pregnancy and lactation with patients of childbearing potential 6
  • Guidelines recommend considering rimegepant specifically in nonpregnant outpatient adults who fail triptan therapy 6

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.